A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Stopped early · Phase 1

Conditions studied: Neoplasms

In brief

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.

Key facts

Study ID

NCT03783403

Run by

Celgene

People needed

206

Starts

2019-03-01

Expected to finish

2024-08-05

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or CD20-positive non-Hodgkin's lymphoma, or diffuse large B cell lymphoma, or follicular lymphoma
• Solid tumors must have at least one site of measurable disease as determined by RECIST v1.1
• Eastern cooperative oncology group performance status of 0 or 1

You may not qualify if…

• High-grade lymphomas (Burkitt's or lymphoblastic)
• Has cancer with symptomatic central nervous system (CNS) involvement
• History of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 105 — Birmingham, Alabama, United States
• Local Institution - 101 — Scottsdale, Arizona, United States
• Local Institution - 112 — Sacramento, California, United States
• Rocky Mountain Cancer Centers, LLP [Aurora-COAU] — Aurora, Colorado, United States
• Local Institution - 115 — St Louis, Missouri, United States
• Local Institution - 110 — New York, New York, United States
• Local Institution - 109 — Charlotte, North Carolina, United States
• Local Institution - 106 — Oklahoma City, Oklahoma, United States
• Local Institution - 113 — Portland, Oregon, United States
• Local Institution - 107 — Pittsburgh, Pennsylvania, United States
• Local Institution - 102 — Nashville, Tennessee, United States
• Local Institution - 108 — Houston, Texas, United States
• Local Institution - 103 — San Antonio, Texas, United States
• Local Institution - 301 — Heidelberg, Victoria, Australia
• Local Institution - 303 — Melbourne, Victoria, Australia
• Local Institution - 201 — Edmonton, Alberta, Canada
• Local Institution - 202 — Toronto, Ontario, Canada
• Local Institution - 402 — Borddeaux Cedex, France
• Local Institution - 406 — Créteil, France
• Local Institution - 405 — Marseille, France
• Local Institution - 404 — Nantes, France
• Local Institution - 403 — Rouen, France
• Local Institution - 401 — Villejuif, France
• Local Institution - 604 — Seoul, South Korea
• Local Institution - 603 — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.